Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics. 2013 Jan;14(2):205-13. doi: 10.2217/pgs.12.205.

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.

Author information

1
UNC School of Medicine, Division of Cardiology, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599-7075, USA. bcjensen@med.unc.edu

Abstract

Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strategies focus on surveillance rather than prevention, although there are no specific therapies for this highly morbid adverse effect. Current models for prospectively predicting risk of chemotherapeutic cardiotoxicity are limited. Cardiotoxicity can occur idiosyncratically in patients without obvious demographic risk factors, suggesting a genetically determined susceptibility, and candidate-gene studies have identified a limited number of variants that increase risk. In this commentary we indicate a need for more powerful means to identify risk prospectively, and suggest that broad pharmacogenomic approaches may be fruitful.

PMID:
23327580
PMCID:
PMC3582022
DOI:
10.2217/pgs.12.205
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center